title: Rituximab-induced lung disease.
abstract: Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been reported and may cause mortality despite early detection. Typically the pulmonary toxicity occurs at around the fourth cycle of Rituximab. High index of suspicion is crucial and other concurrent pathology such as infective causes should be excluded. Radiological imaging and histological confirmation should be obtained and early treatment with corticosteroid should be initiated. Patients should receive counselling regarding respiratory symptoms and possible pulmonary toxicity.
authors: Universiti Kebangsaan Malaysia Medical Centre, Faculty of Medicine, Cell Therapy Centre, Kuala Lumpur, Malaysia. wanfariza@ppukm.ukm.edu.my.
authors: W A
authors: WA
authors: Wan Zaidi
authors: Universiti Kebangsaan Malaysia Medical Centre, Faculty of Medicine, Cell Therapy Centre, Kuala Lumpur, Malaysia.
authors: W F
authors: WF
authors: Wan Jamaludin
authors: Universiti Kebangsaan Malaysia Medical Centre, Faculty of Medicine, Cell Therapy Centre, Kuala Lumpur, Malaysia.
authors: N R
authors: NR
authors: Tumian
authors: Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
authors: S F
authors: SF
authors: Abdul Wahid
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D000069283:Rituximab / Q000009:adverse effects*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab